Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2012

Global Markets Direct, November 2012, Pages: 38

Haemophilus Influenzae Type b Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections. Haemophilus Influenzae Type b Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Haemophilus Influenzae Type b Infections.
- A review of the Haemophilus Influenzae Type b Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Haemophilus Influenzae Type b Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Type b Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Type b Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Haemophilus Influenzae Type b Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Haemophilus Influenzae Type b Infections 7
Haemophilus Influenzae Type b Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Pre-Clinical Stage Products 11
Comparative Analysis 11
Haemophilus Influenzae Type b Infections Therapeutics – Products under Development by Companies 12
Companies Involved in Haemophilus Influenzae Type b Infections Therapeutics Development 13
Merck & Co., Inc. 13
LG Life Sciences, Ltd 14
Sinovac Biotech Ltd. 15
Haemophilus Influenzae Type b Infections – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Hib Vaccine - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
DTP-HepB-Polio-Hib - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
DTP-HepB-Polio-Hib - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DTP-HepB/Hib Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
V-419 + Prevnar 13 + RotaTeq - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 29
NU-300 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Hexaxim - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Haemophilus Influenzae Type b Infections Therapeutics – Drug Profile Updates 32
Haemophilus Influenzae Type b Infections Therapeutics - Dormant Products 34
Haemophilus Influenzae Type b Infections – Product Development Milestones 35
Featured News & Press Releases 35
Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 35
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 35
Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products Under Development for Haemophilus Influenzae Type b Infections, H2 2012 7
Products under Development for Haemophilus Influenzae Type b Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Merck & Co., Inc., H2 2012 13
LG Life Sciences, Ltd, H2 2012 14
Sinovac Biotech Ltd., H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Haemophilus Influenzae Type b Infections Therapeutics – Drug Profile Updates 32
Haemophilus Influenzae Type b Infections Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Haemophilus Influenzae Type b Infections, H2 2012 7
Products under Development for Haemophilus Influenzae Type b Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Customers who bought this item also bought

• Bordetella Pertussis Infections - Pipeline Review, H2 2012
• Respiratory Tract Infections - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Clostridium Botulinum Infections - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis
• Urinary Tract Infections - Pipeline Review, H2 2012
• Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2012
• Rotavirus Infections - Pipeline Review, H2 2012